Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 944-482-9 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Skin sensitisation (OECD TG 429): sensitising; EC3 and NOEC are 3% and 1%, respectively
HRIPT test: at 5%: not sensitising.
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 04 April 2001, 11 April 2001
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: The study is considered to be a reliability 2 as it has been conducted according to OECD Test Guideline 429 (Draft Nov. 2000) using the Skin Sensitisation: Local Lymph Node Assay method, without GLP.
- Justification for type of information:
- The LLNA study is justified because the test was carried out before the availability of in vitro sensitisation methods
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
- Version / remarks:
- Draft November 2000
- Deviations:
- no
- GLP compliance:
- no
- Type of study:
- mouse local lymph node assay (LLNA)
- Species:
- mouse
- Strain:
- other: CBA/CaOlaHsd
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Harlan Netherlands B.V., Postbus 6174, NL-5960 AD Horst, The Netherlands
- Age at study initiation: 6 - 8 weeks (beginning of acclimatization period)
- Weight at study initiation: 15.0 - 20.9 g (beginning of acclimatization period)
- Housing: In groups of four in Makrolon type-3 cages with standard softwoord bedding.
- Diet: Free access to pelleted standard Kliba 3433, batch no. 06/00 mouse maintenance diet (Provimi Kliba AG, CH-4132 Muttenz)
- Water: Free access to community tap water
- Acclimation period: Under test conditions after health examination, for 7 days.
ENVIRONMENTAL CONDITIONS (target ranges)
- Temperature (°C): 22 ± 3
- Humidity (%): 30 - 70
- Air changes (per hr): 10 - 15
- Photoperiod (hrs dark / hrs light): 12/12 - Vehicle:
- acetone/olive oil (4:1 v/v)
- Concentration:
- Undiluted test item (100%) or the test item at concentrations of 0.1%, 1% or 10% v/v in vehicle.
- No. of animals per dose:
- Groups of four mice were treated.
- Details on study design:
- The test item in the main study was assayed at four consecutive concentrations.
TREATMENT PROCEDURES:
TOPICAL APPLICATION:
Each test group of mice was treated by topical (epidermal) application to the dorsal surface of each ear lobe (left and right) with different test item concentrations of 0.1 %, 1 %, 1 0 % and 100 % (undiluted) in acetone:olive oil, 4:1 (v/v). The application volume, 25 µL, was spread over the entire dorsal surface of each ear lobe once daily for three consecutive days. A further group of mice was treated with an equivalent volume of the relevant vehicle alone (control animals). A hair dryer was used to dry the ear's surface as quickly as possible to avoid loss of test item applied.
ADMINISTRATION OF 3H-METHYL THYMIDINE:
3H-methyl thymidine 3HTdR) was purchased from Amersham International (Amersham product code no. TRA 31 0; specific activity, 2 Ci/mmol; concentration, 1 mCi/mL). Five days after the first topical application, all mice were administered with 250 µL of 84.78 µCi/mi 3HTdR (equal to 21.2 µCi 3HTdR) by intravenous injection via a tail vein.
DETERMINATION OF INCORPORATED 3HTdR:
Approximately five hours after treatment with 3HTdR all mice were euthanized by intraperitoneal injection of NARCOREN (Rhone Merieux GmbH, D-88471 Laupheim) at a dose of at least 2 mL/kg body weight (equivalent to 320 mg sodium pentobarbitone/kg body weight).
The draining lymph nodes were rapidly excised and pooled for each experimental group (8 nodes per group except for groups 4 and 5 where only 7 lymph nodes were found). Single cell suspensions (phosphate buffered saline) of pooled lymph node cells were prepared by gentle mechanical disaggregation through stainless steel gauze (200 µm mesh size). After washing three times with phosphate buffered saline (approx. 10 mL) the lymph node cells were resuspended in 5% trichloroacetic acid (approx. 3 mL) and incubated at approximately +4 °C overnight for precipitation of macromolecules. The precipitates were then resuspended in 5% trichloroacetic acid (1 mL) and transferred to glass scintillation vials with 10 mL of 'Ultima Gold' scintillation liquid and thoroughly mixed.
The level of 3HTdR incorporation was then measured on a β-scintillation counter. Similarly, background 3HTdR levels were also measured in two 1 ml-aliquots of 5% trichloroacetic acid. The β-scintillation counter expresses 3HTdR incorporation as the number of radioactive disintegrations per minute (DPM).
OBSERVATIONS:
Mortality / Viability: Twice daily from acclimatization to the termination of in-life phase.
Body weights: At acclimatization start and prior to necropsy.
Clinical signs (local / systemic): Daily from acclimatization start to the termination of in-life phase. Especially the treatment sites were recorded carefully. - Positive control substance(s):
- hexyl cinnamic aldehyde (CAS No 101-86-0)
- Statistics:
- Not performed.
- Positive control results:
- The positive control item, hexyl cinnamic aldehyde, gave a Stimulation Index of 3.7 and 7.0 when tested at a concentration of 10 and 25 % v/v, respectively, in acetone/olive oil 4:1.
- Key result
- Parameter:
- EC3
- Remarks:
- %
- Value:
- 3
- Parameter:
- SI
- Remarks on result:
- other: The SI values calculated for the substance concentrations 0.1, 1, 10 and 100% were 0.9, 0.9, 10.4 and 17.5, respectively.
- Key result
- Parameter:
- other: NOEC
- Remarks:
- %
- Value:
- 1
- Interpretation of results:
- other: sensitising.
- Remarks:
- According to Regulation (EC) No. 1272/2008.
- Conclusions:
- The SI values calculated for the substance concentrations 0.1, 1, 10 and 100% were 0.9, 0.9, 10.4 and 17.5, respectively. These results show that the test substance could elicit a SI ≥ 3. An EC3 has been derived resulted in an EC3 of 3%. A NOAEC of 1% is derived. The test substance was considered to be a sensitiser under the conditions of the test.
- Executive summary:
The skin sensitisation potential of the substance has been tested according to OECD TG 429: Local Lymph Node Assay" method (draft November 2000), non-GLP. At 0.1, 1, 10 and 100% the substance showed SI values of 0.9, 0.9, 10.4 and 17.5, respectively. Reliable negative and positive controls were included.
No symptoms of local toxicity at the ears of the animals and no systemic findings were observed during the study period. These results show that the test substance could elicit a SI ≥ 3.
An EC3 has been derived resulted in an EC3 of 3%. A NOEC of 1% is derived.
according to Regulation (EC) No. 1272/2008 and GHS.
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed (sensitising)
- Additional information:
The starting value for the risk characterization is based on the LLNA because the skin sensitisation value in ug/cm2 is the more conservative value compared to the HRIPT:
The NOEC from the LLNAof 1% is converted to 232 ug/cm2 (based on an application volume of 25μL, an application area of 1 cm2and the relative density of the substance (0.926g/mL OR when using the ECHA guidance 1*250=250 ug/cm2, using a density of 1).
The NOEC of 5% in the HRIPT results in 2550 ug/cm2 (based on an application volume of 200 ul and application area at 3.63 cm2 x 0.926 density).
The summary of the LLNA is presented below and thereafter the HRIPT test.
LLNA test:
The skin sensitisation potential of the substance has been tested according to OECD TG 429: Local Lymph Node Assay" method (draft November 2000), non-GLP. At 0.1, 1, 10 and 100% the substance showed SI values of 0.9, 0.9, 10.4 and 17.5, respectively. Reliable negative and positive controls were included.
No symptoms of local toxicity at the ears of the animals and no systemic findings were observed during the study period. These results show that the test substance could elicit a SI ≥ 3.
An EC3 has been derived resulted in an EC3 of 3%. A NOEC of 1% is derived.
HRIPT test:
In a repeated insult patch test, approximately 0.2 mL of 5% in Alcohol SD39C:DEP (75:25) was applied directly to an occluded patch, which was placed to the back of each subject between the scapulae and waist, adjacent to the spinal mid-line. This procedure was repeated every Monday, Wednesday and Friday until 9 applications of the test substance had been made. The patches remained in place for 24 hours and application sites were scored for dermal responses just prior to the next patch application.
Approximately 2 weeks after application of the last induction patch, a challenge patch was applied to a previously unpatched (virgin) test site. Twenty-four hours later, the patch was removed and sites were scored at 24, 48, and 72 hours after application of the challenge patch.
During the Challenge phase, bare perceptible (+) responses were observed on three (3/105) test panellists at the 24 -hour evaluation. By the 48 -hour evaluation, no response was noted. Due to the low severity and transient nature of these responses, they are not considered to be evidence of sensitisation. The NOAEC from this study is therefore 5%.
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not sensitising)
- Additional information:
The substance is not a skin sensitiser because there are no human data that indicate respiratory skin sensitisation. In addition the potential for respiratory sensitization of the substance is assessed using the integrated evaluation strategy for respiratory sensitization data in the ECHA guidance (R7A, Fig. 7.3-2).
1) The substance is a weak skin sensitizer;
2) The substance does not belong to the di-isocyanates;
3) The substance has not structural alerts or is structurally related to chemicals causing respiratory sensitization as presented in Table R.7.3-1 in the ECHA guidance of 2008 or those provided in the following document: http://ec.europa.eu/health/scientific_committees/docs/annex6_respiratory.pdf
Using this ITS in the ECHA guidance it can be concluded that Galbascone is not a respiratory sensitiser.
Justification for classification or non-classification
The substance was considered to be a sensitiser and should be classified as skin sensitizer (Category 1B) and labeled as H317: May cause an allergic skin reaction according to Regulation (EC) No. 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.